TD Cowen analyst Marc Frahm reiterated a Buy rating on Elevation Oncology (NASDAQ: ELEV).The analyst commented, "ELEV reported Q2 financials ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE